Three lines of evidence promote the search for a new type of anti-cancer agent possessing a higher anti-inflammatory activity, targeting high-mobility group box 1 (HMGB1)–receptor for advanced glycation end-products (RAGE) signaling pathway in the tumor microenvironment (TME). Here, AGER is linked to neoplasm.